Literature DB >> 25992217

The management of low-stage non-seminomatous germ cell tumors.

Louise Lim1, Thomas Powles1.   

Abstract

The prognosis of patients with stage I non-seminomatous germ cell tumors is in general very good. However, a large number of patients relapse with metastatic disease after orchidectomy Therefore, adjuvant treatment, in the form of either chemotherapy or retroperitoneal dissection is recommended, although active surveillance has been found to be as good a way of treating these patients with overall excellent results.

Entities:  

Keywords:  adjuvant therapy.; non-seminomatous germ cell cancer; surveillance

Year:  2012        PMID： 25992217      PMCID： PMC4419627          DOI： 10.4081/oncol.2012.e19

Source DB:  PubMed          Journal:  Oncol Rev        ISSN： 1970-5557


  35 in total

Review 1.  The role of retroperitoneal lymph node dissection in the management of testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2004 May-Jun       Impact factor: 3.498

2.  Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone.

Authors:  L S Freedman; M C Parkinson; W G Jones; R T Oliver; M J Peckham; G Read; E S Newlands; C J Williams
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

3.  Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.

Authors:  Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

5.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Authors:  M H Cullen; S P Stenning; M C Parkinson; S D Fossa; S B Kaye; A H Horwich; S J Harland; M V Williams; R Jakes
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

Review 6.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

7.  Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.

Authors:  Carvell T Nguyen; Alex Z Fu; Timothy D Gilligan; Brian J Wells; Eric A Klein; Michael W Kattan; Andrew J Stephenson
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy.

Authors:  R T D Oliver; J Ong; J Shamash; R Ravi; V Nagund; P Harper; M J Ostrowski; B Sizer; J Levay; A Robinson; D E Neal; M Williams
Journal:  Urology       Date:  2004-03       Impact factor: 2.649

9.  Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).

Authors:  D P Dearnaley; S D Fossa; S B Kaye; M H Cullen; S J Harland; M P J Sokal; J D Graham; J T Roberts; G M Mead; M V Williams; P A Cook; S P Stenning
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

10.  Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

Authors:  Gordon J Rustin; Graham M Mead; Sally P Stenning; Paul A Vasey; Nina Aass; Robert A Huddart; Michael P Sokal; Jonathan K Joffe; Stephen J Harland; Sarah J Kirk
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.